Patient or Disabled Group
Guided by data, Mosaic licenses two cancer compounds from Astex
Astex, Spatial Mosaic, ASTX029, MDM2 Antagonist ASTX295
HR25: LifeSignals launches cardiac monitoring patch to compete with iRhythm, Philips
Preventive monitoring, Plaque (lesion), Philips, Heart, iRhythm, LifeSignals, Medical Devices
UK approval brings GSK’s Blenrep back from the brink
UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life
Pharma’s wins and losses in Trump’s sprawling executive order on drug prices
Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices
Glycomine raises $115M to see if it can treat rare glycosylation disorder
Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A
Sanofi tempers its OX40 expectations in asthma after mid-stage miss
Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations
Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly
Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Myasthenia Gravis, Cell Therapy, Long-term, Cartesian
Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed
Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome